Cumbers says Novo Nordisk has worked on internal AI for decades and got into LLMs early, and calls the company at a turning point.
Recap by typeshit. Post by John Cumbers on X.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
The writer cites a Gallup survey putting about 11 percent of Americans on GLP-1s and argues the real share is likely higher, and wants use discussed openly.
11:37
A 63 year old creator walks through six months on tirzepatide and a 48 pound drop, sharing a personal account of the experience.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
Post hoc analyses published in the Journal of Clinical Sleep Medicine check how baseline traits shaped tirzepatide results in people with sleep apnea and obesity.
The interim access policy went to OMB review, and Hims & Hers shares rose nearly 6%. Leerink sizes the possible market at $2.2B a year.
Loading…